Hormones and longevity: menopause, optimization and where experts draw lines

The Short Version

Midlife hormone changes reach well beyond fertility. Neuroscientist Lisa Mosconi argues that menopause is a neurological transition, and that the steep drop in estrogen helps explain why nearly two-thirds of Alzheimer's patients are women [1]. Physician Peter Attia adds bone to the picture and argues that modern hormone therapy for women was wrongly scared off by a flawed study, but he draws firm lines on testosterone: he measures carefully, doses conservatively, rarely treats men under about 40, and uses hormones only to help people do the hard work [3]. Craig Koniver is the most enthusiastic of the three, using peptides that coax the body's own growth hormone plus testosterone and even nandrolone for select patients, though his case rests mainly on clinical observation rather than trials and he warns hard against unsupervised use [2]. The common ground is that hormones deserve informed attention, measured levels and a physician's guidance. Where the experts differ is on how far to push.

Table of contents

What They Said

Lisa Mosconi: menopause is a brain event

Mosconi, founder of the Women's Brain Initiative, starts from a statistic: nearly two-thirds of all Alzheimer's patients are women [1]. The usual explanation is that women live longer. Mosconi rejects that as the whole story. Her research points to hormones [1].

Her argument goes like this. During menopause, women's brains go through a sharp drop in estrogen [1]. Estrogen matters to the brain for energy metabolism, immune response, neuroplasticity and glucose processing [1]. Men's hormones decline gradually, but women face a steep drop-off, which causes rapid changes in brain function [1]. Her summary line: "Estrogen isn't just a reproductive hormone. It's a superpower for your brain." [1]

So she calls menopause a neurological transition, not just a reproductive one [1]. Outcomes vary. For some women, cognitive function recovers after menopause. For others, it deteriorates into early signs of Alzheimer's [1]. That split is the heart of why she thinks the transition deserves attention: it is a window when the brain's path can go either way.

Two further points sharpen her case. Women who go through surgical menopause, meaning removal of the ovaries or uterus, show a higher risk of dementia, especially without supportive therapy [1]. And brain fog, one of the top complaints in her clinical work, is often driven partly by poor hormonal regulation, especially in perimenopausal women, along with mild dehydration and low antioxidant intake [1].

On treatment, Mosconi takes a middle position. Hormone replacement therapy may help some women, but not all [1]. Phytoestrogens, plant compounds that act somewhat like estrogen, may offer a gentler alternative [1]. She lists flaxseeds, sesame seeds, chickpeas, soy, dried figs and apricots as sources, and says they have been shown to help mimic estrogen's protective effects [1]. The rest of her brain-protection plan is food and hydration: berries, dark leafy greens, omega-3 fats, water with electrolytes, and fewer processed foods [1]. Her lab's MRI scans show visible brain deterioration by age 50 in people eating processed food, compared with better brain structure in those on plant-rich, Mediterranean-style diets [1]. "Your brain literally shrinks on a processed food diet—and plaques can form decades before symptoms appear." [1]

Peter Attia: hormone therapy, reconsidered, with firm lines

Attia comes to hormones through his longevity framework. Lifespan is mostly threatened by four diseases: heart disease, cancer, neurodegenerative disease and metabolic disease [3]. Healthspan covers cognitive, physical and emotional quality of life [3]. Hormones touch several of these at once.

Bone. Attia says bone density matters enormously, especially for women around menopause, because estrogen is the most important hormone regulating bone [3]. Bone mass builds until about age 20 to 25, plateaus until 50, then declines slowly in men and steeply in women [3]. The stakes: after 65, breaking a hip carries roughly a 30 to 40% chance of death within a year [3]. He tracks bone with DEXA scans and aims to move the Z-score, a comparison with people of your age and sex, upward over time [3]. His non-hormonal tool is heavy strength training, which his team's review found beats running for bone, and he cites an Australian study in which older women with osteopenia who had never lifted learned deadlifts and good mornings with heavy loads and improved their bone health [3].

Menopause symptoms. Menopause brings hot flashes and night sweats, then vaginal atrophy, bone loss and brain fog [3]. That brain fog point connects directly to Mosconi's concerns [1][3]. Attia also explains that, measured in the same units, women have more testosterone than estrogen, and that PMS symptoms track the steep late-cycle drop in progesterone and can often be relieved with low-dose progesterone [3].

The Women's Health Initiative. Attia's sharpest point is about the study that made hormone therapy frightening. He calls it "hands down the biggest screw up of the entire medical field in the last 25 years." [3] His criticisms [3]:

• It enrolled women far past menopause.
• The women were disproportionately unhealthy, with many smokers and high rates of obesity and diabetes.
• It deliberately excluded women with symptoms.
• It used horse-derived estrogen with a synthetic progestin (MPA), not the bioidentical hormones used today.
• Its famous headline, a 25 to 27% increase in breast cancer, reflected a rise from about four to five cases per thousand women, an absolute increase of 0.1%.
• In the estrogen-only arm, breast cancer actually trended about 24% lower, which suggests MPA was the problem.

His rule for reading such results: "you never talk about a relative risk change without an absolute risk accommodating it." [3]

What he uses instead. Oral estrogen raises clotting risk, but modern patches do not, he says [3]. He uses a bioidentical estradiol patch plus micronized progesterone for women with a uterus; if progesterone isn't tolerated, a progesterone-releasing IUD protects the uterus [3].

Where he gets cautious. Testosterone for women is a line he approaches slowly because data are lacking. He uses topical testosterone only to restore normal levels in women with very low levels, low libido and difficulty building muscle [3].

Testosterone for men. Attia's approach is precise and conservative. He focuses on free testosterone, the unbound, active portion, ideally around 2% of total, rather than total testosterone [3]. The binding protein SHBG is shaped by genetics and three hormones: estradiol and thyroxine raise it, and insulin lowers it, which means that becoming more metabolically healthy on a low-carbohydrate diet can temporarily lower free testosterone [3]. He wants estradiol around 30 to 50 and never below about 25, citing a study in which men were chemically castrated and given five doses of testosterone with or without anastrozole, where the best outcomes came with high testosterone and estradiol in that range [3]. Only about 20% of his patients need a tiny compounded dose of anastrozole [3].

His lines on men's therapy [3]:

• When the problem is a weak signal from the pituitary, the aim is to restart the body's own production.
• He stopped using clomiphene after noticing it raises desmosterol, a cholesterol precursor; a 1960s drug that acted on the same enzyme lowered cholesterol but increased cardiac events and was withdrawn. He now uses HCG, which preserves testicular size and function, especially for men who want fertility.
• He stopped using microdoses of Anavar to lower SHBG after one patient swallowed it and tripled his liver enzymes.
• When he prescribes testosterone, it is testosterone cypionate injected under the skin, usually no more than 100 milligrams a week split into doses, compared with 500 to 1,000 for bodybuilders.
• He avoids pellets and has rarely treated anyone under about 40.

He is also cautious about testosterone-boosting supplements. He and Huberman note that long-term safety data are lacking for tongkat ali and Fadogia agrestis, and Huberman says stinging nettle lowered his DHT, so he stopped [3].

Attia's philosophy fits in one sentence: "really the only purpose in my mind of fixing testosterone is to give you the capacity to work harder." [3] He points out that his own best physique came at 38, when his testosterone was very low from overtraining [3]. Huberman adds that young men should fix sleep, exercise, nutrition and social connection first [3].

Beyond sex hormones. On peptides such as BPC-157, Attia is curious but skeptical, calling the field "wild, wild west" [3]. He tried BPC-157 with a colleague for a couple of months and didn't notice a single thing [3]. His bigger worry is that such treatments become a crutch: after shoulder surgery he spends about an hour four days a week on tedious rehab, because "you just got to do the work and it's freaking hard." [3] He supports rapamycin because of consistent evidence across many organisms and hopes it will be tested for preserving ovarian function [3]. On GLP-1 drugs, he hopes, as with hormones, that they help people do the hard behavioral work rather than replacing it [3].

Craig Koniver: performance medicine and hormone-adjacent peptides

Koniver practices what he calls "performance medicine," using peptides and hormones for health, performance and longevity [2]. His enthusiasm is clearly greater than Attia's, and both he and Huberman say openly that much of what he shares comes from years of clinical observation rather than published trials [2].

Why peptides. Huberman frames the logic. Hormone therapies such as growth hormone and testosterone "are in fact hormones, but they actually can shut down one's natural production of those hormone pathways." [2] Peptides, by contrast, "sit somewhere between doing nothing and supplementation, and those more advanced hormone therapies," and "they don't tend to operate in that negative feedback cycle by shutting down one's own endogenous production." [2] He adds that this doesn't mean they are free of safety concerns [2].

Growth hormone secretagogues. These peptides prompt the body to release its own growth hormone. Koniver explains the pathway: ipamorelin prompts the pituitary to release growth hormone, which drives the liver to make IGF-1, an anabolic, healing hormone that declines with age [2]. He calls growth hormone a resiliency hormone, useful for people who recover slowly from workouts, sprains or cuts [2]. Because the largest growth hormone pulse is thought to occur between about 10 p.m. and 2 a.m., he recommends injecting at bedtime, with no food for at least 45 minutes beforehand [2]. He sets 100 micrograms of ipamorelin as the maximum effective dose, warning that he has heard of anaphylaxis when people push to 200 to 400 micrograms [2].

Each peptide, he says, has its own "flavor [2]. Ipamorelin is the cleanest: leaner body, better sleep, few side effects. GHRP-6 is more potent but also releases prolactin and ACTH (which drives cortisol) and spikes appetite. MK-677 works orally but made him ravenously hungry, though it can help older adults struggling to build muscle. Tesamorelin is FDA-approved for visceral fat in HIV-related lipodystrophy and, in his experience, works better in women [2]. He uses five-days-on, two-days-off schedules, because, as he puts it, Anything you expose yourself to continually, doesn't work as well." [2]

Individual responses vary, and Huberman supplies a cautionary example: sermorelin gave him great early-night sleep but wiped out his REM sleep in the second half of the night and consistently raised his PSA [2].

Testosterone and nandrolone. Huberman notes the conversation covers "testosterone therapies, not just for men, but for women." [2] Koniver describes nandrolone as the one anabolic steroid physicians can legitimately prescribe alongside testosterone, and he used the combination to restore mobility in a patient in his 80s, a former Marine and Secret Service agent with bone loss [2]. That is further than Attia goes in these sources.

Where Koniver draws lines. He dislikes testosterone pellets because they expose people to hormone levels never seen in nature [2], the same line Attia draws [3]. His strongest warning is a story about a 25-year-old who had used testosterone and growth hormone since his late teens. Koniver says of how the young man felt, "he was Superman." [2] Then he wanted children: "Now there's a repercussion for this. And I've seen that time and time again, and the repercussion is big." [2] The man had zero sperm, and "now you got to come off the testosterone. You got to rebuild your system," using drugs such as clomiphene and HCG [2]. Huberman stresses that most men from their teens to early 40s don't need synthetic testosterone if they sleep, eat and train well [2].

Koniver is equally firm on supervision and sourcing. He tells of a patient who, on a TV doctor's advice, took an oral weight-loss compound and came in with terrible headaches and a blood pressure he estimates at around 220 over 140 [2]. "So the problem is people have access to all this information. But if they're not under the guidance of a doctor to help clean up the mess," things can go wrong [2]. He draws a sharp line between compounding pharmacies, which are regulated, inspected and must test sterile products for purity and endotoxins, and gray-market "research" peptides, which may contain the inflammatory toxin LPS and have caused anaphylactic reactions [2].

The regulatory backdrop. The FDA placed BPC-157 and many other peptides on a list that bars compounding pharmacies from making them in October 2023 [2]. Koniver thinks the motive is "probably both: good intentions to regulate a wild, wild west," plus overreach, alongside drug companies that may see a path to expensive branded versions [2]. Huberman notes a late update: three peptides, including the growth hormone secretagogues CJC-1295 and ipamorelin, had been allowed again for prescription [2]. The rules are shifting fast.

Where They Agree, and Where They Don't

Where they agree.

Hormones matter beyond reproduction. Mosconi ties estrogen to brain energy, immunity, plasticity and glucose use [1]. Attia ties it to bone and to menopausal brain fog [3]. Koniver ties growth hormone and IGF-1 to healing and resilience [2]. All three treat midlife hormone decline as a health issue, not just a fertility milestone.

Individual variation. Mosconi says some women recover cognitively after menopause while others decline, and hormone therapy helps some but not all [1]. Attia personalizes by measuring free testosterone, estradiol and bone Z-scores [3]. Koniver describes each peptide's different "flavor" and Huberman's own unusual responses [2].

No pellets, no supraphysiological levels, no unsupervised use. Attia and Koniver both avoid pellets [2][3]. Both stress preserving the body's own production and fertility, Attia with HCG [3], Koniver in his 25-year-old story [2]. Both say young men mostly don't need testosterone if their basics are in order, with Huberman making the point in both conversations [2][3].

Hormones should support effort, not replace it. Attia's purpose for testosterone is the capacity to work harder [3]. Koniver describes his tools as helping people feel better so they have the energy to pursue their purpose [2].

Where they differ.

How enthusiastic to be. Koniver uses growth hormone secretagogues, peptide stacks and even nandrolone for selected patients [2]. Attia calls the peptide world "wild, wild west" and noticed nothing from BPC-157 [3]. The reason for the gap is evidence standards: Attia wants consistent data across organisms, as with rapamycin, and reads trials critically [3], while Koniver relies on what he has seen in thousands of patients, which both he and Huberman acknowledge is not trial data [2].

Estrogen therapy versus food. Attia is clearly supportive of modern transdermal estradiol with micronized progesterone for women with a uterus [3]. Mosconi is more reserved: hormone therapy helps some but not all women, and phytoestrogens from food may be a gentler alternative [1]. Attia doesn't discuss phytoestrogens, and Mosconi doesn't discuss the WHI; they aren't directly contradicting each other, but a woman hearing only one would get a different emphasis.

Testosterone for women. Huberman says Koniver's conversation covers testosterone therapies for women and notes they are growing in popularity [2]. Attia is more cautious, using it only to restore physiologic levels in women with very low levels and specific symptoms, because data are lacking [3].

Why women get Alzheimer's more often. Mosconi's view is that the steep estrogen drop, not just longer life, explains much of it [1]. Attia's dementia framework in this source emphasizes exercise as the most effective prevention, plus cardiovascular risk and genes like APOE [3]. These are complementary, not contradictory, but they point to different first moves.

Why It Works

The sources describe several mechanisms.

Estrogen as brain fuel manager. Estrogen supports energy metabolism, immune response, neuroplasticity and glucose processing in the brain [1]. A steep drop, as in menopause, rapidly changes brain function [1]. Surgical menopause, which drops hormones abruptly, carries a higher dementia risk, especially without supportive therapy [1].

Estrogen and bone. Estrogen is the most important hormone regulating bone, which is why women's bone mass falls steeply after 50 [3]. Loss of bone raises fracture risk, and hip fractures after 65 carry a 30 to 40% one-year death risk [3]. Heavy loading works because muscles pull on bone through tendons, stimulating bone-building cells [3].

Formulation and route matter. Attia's reading of the WHI is that the harms came from the specific drugs (horse estrogen plus synthetic MPA), the route (oral estrogen raises clotting risk, patches don't) and the population (older, unhealthy women without symptoms) [3]. In the estrogen-only arm breast cancer trended lower [3].

Free versus total hormone. Only unbound testosterone is active, and SHBG sets how much is free [3]. Because insulin lowers SHBG, metabolic changes shift hormone levels, which is why diet can temporarily lower free testosterone [3]. Estradiol matters in men too, and the best outcomes in the castration study came with estradiol around 30 to 50 [3].

Negative feedback. Taking a hormone directly signals the body to stop making its own, which is how years of testosterone and growth hormone left a 25-year-old with zero sperm [2]. Peptides that prompt the pituitary to release growth hormone don't tend to trigger that shutdown, as Huberman describes it [2], and HCG preserves testicular function during therapy [3].

Timing with the body's rhythm. Koniver times growth hormone secretagogues to bedtime because the largest natural pulse comes between about 10 p.m. and 2 a.m. [2].

Where It Applies, and Where It Doesn't

It applies most to:

• Women approaching or in menopause, especially with brain fog, hot flashes or bone loss [1][3]. Mosconi and Attia both treat this as a window worth attention.
• Women who have had their ovaries or uterus removed, who show higher dementia risk without supportive therapy [1].
• Women whose bone density is falling, for whom estrogen and heavy strength training both matter [3].
• Older men with genuinely low levels and symptoms, treated conservatively by a physician who measures free testosterone and estradiol and protects fertility where needed [3].
• Older adults struggling to build muscle or recover, where Koniver sees a role for growth hormone secretagogues [2], and severe cases like his patient in his 80s with bone loss [2].

It applies less, or not at all:

• Young men. Attia rarely treats men under about 40, and Huberman says most men from their teens to early 40s don't need testosterone if they sleep, eat and train well [2][3]. The 25-year-old's infertility shows the cost [2].
• Anyone without a physician. Koniver's headache and blood pressure story and the risk of contaminated research peptides make supervised, properly sourced treatment the only version any of these experts endorses [2].
• Women seeking testosterone without clear low levels and symptoms, where Attia says data are lacking [3].
• Every woman at menopause. Mosconi says hormone therapy may help some but not all [1].
• Peptides as a proven longevity tool. Attia found no effect from BPC-157 and considers the field unproven [3]; Koniver's evidence is clinical experience [2]; and the legal status of many peptides keeps changing [2].
• A replacement for the basics. Attia's test for testosterone is whether it helps you work harder [3], and his bone advice starts with heavy lifting [3]. Mosconi's brain plan starts with food and hydration [1].

Hormone therapy decisions depend on personal history, including cancer risk, clotting risk and fertility plans, so make them with a physician experienced in hormone care.

What To Do With It

1. Treat menopause as a brain and bone event, and plan for it. Mosconi calls it a neurological transition [1], and Attia notes bone falls steeply in women after 50 [3]. Talk with a doctor about symptoms such as brain fog, hot flashes and night sweats before they become a crisis [1][3].

2. Revisit hormone therapy with absolute risk in mind. If you ruled out hormone therapy because of the WHI, ask about the absolute numbers Attia cites (about four versus five breast cancer cases per thousand women) and about modern options: a bioidentical estradiol patch plus micronized progesterone, or a progesterone-releasing IUD if progesterone isn't tolerated [3].

3. If you had surgical menopause, raise dementia risk explicitly. Mosconi says the risk is higher, especially without supportive therapy [1].

4. Add phytoestrogen foods. Flaxseeds, sesame seeds, chickpeas, soy, dried figs and apricots are Mosconi's suggestions for a gentler, food-based way to support estrogen's protective effects [1], alongside berries, leafy greens and omega-3 fats [1].

5. Get a DEXA scan and lift heavy. Track bone density and your Z-score over time, and train with heavy loads; a leg press is fine for beginners [3].

6. Men: measure the right things before treating. Ask for free testosterone (ideally around 2% of total), SHBG and estradiol, not just total testosterone [3]. Remember that improving metabolic health can temporarily lower free testosterone [3].

7. Men under 40: fix the basics first, and protect fertility. Sleep, exercise, nutrition and social connection come first [2][3]. If treatment is ever needed and fertility matters, ask about HCG [3], and don't use testosterone or growth hormone without supervision; the 25-year-old in Koniver's story ended up with zero sperm [2].

8. Avoid pellets and supraphysiological doses. Both Attia and Koniver avoid pellets [2][3], and Attia keeps testosterone cypionate at about 100 milligrams a week or less [3].

9. If you try peptides, use a physician and a compounding pharmacy, not research-grade products. Koniver warns of endotoxin contamination and anaphylaxis from gray-market peptides and caps ipamorelin at 100 micrograms [2]. Expect individual reactions like Huberman's lost REM sleep and higher PSA on sermorelin [2], and check the current legal status, which has changed repeatedly [2].

10. Judge any hormone by what it lets you do. Attia's test is whether it gives you the capacity to work harder [3]; if it becomes a crutch instead of support for the work, rethink it [3].

Sources

1. Optimize Your Brain Health & How to Prevent Alzheimer's with Dr. Lisa Mosconi · The School of Greatness
2. Dr. Craig Koniver: Peptide & Hormone Therapies for Health, Performance & Longevity · Huberman Lab
3. Dr Peter Attia Exercise Nutrition Hormones For Vitality Longevity · Huberman Lab